Australian regulatory action on breast implants and breast tissue expanders
TGA – Australian regulatory action on breast implants and breast tissue expanders
Published in Breast Implant-Associated Anaplastic Large Cell Lymphoma BIA-ALCL, Breast Implants and Therapeutic Goods Administration - TGA
More from Breast Implant-Associated Anaplastic Large Cell Lymphoma BIA-ALCLMore posts in Breast Implant-Associated Anaplastic Large Cell Lymphoma BIA-ALCL »
- EU – SCHEER – Minutes of the Working Group meeting on safety of breast implants in relation to anaplastic large cell lymphoma (BIA-ALCL) of 15 January 2020
- SCHEER Safety of breast implants WG – minutes of 4 November 2019 meeting
- EU – Minutes of the 24 July 2019 SCHEER Working Group on safety of breast implants in relation to anaplastic large cell lymphoma (BIA-ALCL) meeting
- The FDA Takes Action to Protect Patients from Risk of Certain Textured Breast Implants; Requests Allergan Voluntarily Recall Certain Breast Implants and Tissue Expanders from the Market: FDA Safety Communication
- The ANSM decides, as a precautionary measure, to withdraw from the market macrotextured breast implants and breast implants with polyurethane-coated surfaces
More from Breast ImplantsMore posts in Breast Implants »
- EU – SCHEER – Minutes of the Working Group meeting on safety of breast implants in relation to anaplastic large cell lymphoma (BIA-ALCL) of 15 January 2020
- SCHEER Safety of breast implants WG – minutes of 4 November 2019 meeting
- US FDA Draft Guidance – Breast Implants – Certain Labeling Recommendations to Improve Patient Communication
- EU – Minutes of the 24 July 2019 SCHEER Working Group on safety of breast implants in relation to anaplastic large cell lymphoma (BIA-ALCL) meeting
- TGA – Current status of breast implant products in Australia
More from Therapeutic Goods Administration - TGAMore posts in Therapeutic Goods Administration - TGA »
- Australia – TGA – 3-D printing (additive manufacturing) of medical devices
- Australia – TGA – Actual and potential harm caused by medical software
- TGA – Regulation impact statement: Proposed regulatory scheme for personalised medical devices, including 3D-printed devices
- TGA – Medical device application processing times
- TGA guidance – Researcher considerations for medical devices Meeting the evidence requirements for market authorisation
Be First to Comment